| - Quarter Highlighted by Record Net Product Sales, European Launch of Cinryze® (C1 esterase inhibitor [human]) and European Approval of Buccolam® (midazolam, oromucosal solution) - EXTON, Pa., Oct. 27, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the third quarter ended September 30, 2011. In the third quarter of 2011, we: Achieved a record $143 million in net product sales, representing 21 percent growth over the third quarter of ...continued ILNS VPHM Drugs neurosciences Healthcare |
SmallCapUpdates provides the latest news and alerts on stocks for you. If you are looking for the latest on stocks in clean energy, medical innovation, mining, biotech, nanotech, renewable energy, internet technology or in emerging markets.
Pages
▼
No comments:
Post a Comment